Seal The Deal: Curia, Milliporesigma To Expand Cell Line Development

KUALA LUMPUR, June 21 (Bernama) -- Curia, a contract research, development and manufacturing organisation, announced it has signed a licensing agreement with MilliporeSigma, the North American Life Sciences Business of Merck KGaA, Darmstadt, Germany.

The agreement enables Curia and its clients to use the CHOZN GS-/- cell line for production of therapeutic proteins and antibodies, which has been integrated into Curia’s cell line development workflow and is immediately available to Curia customers.

“The CHOZN GS-/- cell line platform adds a widely accepted and commercially viable cell line to our capabilities.

“Our integrated offering accelerates therapeutic protein and antibody production and offers seamless tech transfer for optimal flexibility,” said Curia President R&D, Christopher Conway in a statement.

CHOZN platform is a Chinese Hamster Ovary (CHO) mammalian cell expression system that allows for faster, simpler selection and scale-up of high-producing clones for production of biologics and therapeutic recombinant proteins.

It includes high-performing CHO cell lines, paired media and feeds, optimised expression vectors and robust protocols. The glutamine synthetase GS knockout (GS-/-) cell line of the CHOZN platform is specially designed to help streamline selection, identification and scale-up of high-producing clones ideal for Good Manufacturing Practices (GMP) of recombinant protein drugs.

Curia’s protein and antibody development experts offer a track record of accelerating progress, with a timeline in as little as 12 months from cell line development to phase I drug substance, depending on the manufacturability of the candidates.

The addition of the CHOZN platform strengthens Curia’s offerings as a complement to its existing proprietary CHO cell line, providing customers with a highly versatile and broadly applicable solution.

-- BERNAMA